Communiqués Cessatech A/S

Actions

CESSA

DK0061411964

Cours en clôture NORDIC GROWTH MARKET 28/08/2026			Varia. 5j.	Varia. 1 janv.
11,15 ^DKK	+20,93%		+14,95%	-30,14%

28/08	Cessatech A/S publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
28/08	Cessatech rapporte une perte d'exploitation en légère diminution	FW

Communiqués

28/08	Second Quarter Report Q2-2026	AQ
27/08	CT001 ready for shipment to initial U.S. hospitals as launch activities commence	AQ
03/08	Cessatech: Cessatech – EMA initial KemSu/CT001 opinion Q&A and next steps	PU
03/08	Cessatech - EMA initial KemSu/CT001 opinion Q&A and next steps	AQ
24/07	Cessatech: Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu	PU
24/07	Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu	AQ
12/06	Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children	AQ
28/05	First Quarter Report Q1-2026	AQ
30/03	Minutes from the Annual General Meeting in Cessatech A/S	AQ
13/03	Cessatech convenes its Annual General Meeting	AQ
27/02	Cessatech A/S Announces Financial Results for the Full Year 2025	AQ
02/02	Welcome to the first quarter of 2026	AQ
13/11	Cessatech: Third Quarter Report Q3-2025	PU
13/11	Third Quarter Report Q3-2025	AQ
31/10/25	Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children	PU
31/10/25	CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children	AQ
21/08/25	Cessatech: Second Quarter Report Q2-2025	PU
21/08/25	Second Quarter Report Q2-2025	AQ
14/08/25	Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children	PU
14/08/25	The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children	AQ
27/06/25	Cessatech: Cessatech Q&A – June company presentation	PU
27/06/25	Cessatech Q&A - June company presentation	AQ
19/06/25	Cessatech: Cessatech strengthens Executive Management with the promotion of Martin Juhl	PU
19/06/25	Cessatech strengthens Executive Management with the promotion of Martin Juhl	AQ
11/06/25	Cessatech: Cessatech announce completion of the directed issue of shares	PU